Kummer Laura, Zaradzki Marcin, Vijayan Vijith, Arif Rawa, Weigand Markus A, Immenschuh Stephan, Wagner Andreas H, Larmann Jan
Department of Anesthesiology, University Hospital Heidelberg, Heidelberg, Germany.
Institute of Cardiac Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Front Physiol. 2020 May 8;11:443. doi: 10.3389/fphys.2020.00443. eCollection 2020.
Graft rejection remains the major obstacle after vascularized solid organ transplantation. Endothelial cells, which form the interface between the transplanted graft and the host's immunity, are the first target for host immune cells. During acute cellular rejection endothelial cells are directly attacked by HLA I and II-recognizing NK cells, macrophages, and T cells, and activation of the complement system leads to endothelial cell lysis. The established forms of immunosuppressive therapy provide effective treatment options, but the treatment of chronic rejection of solid organs remains challenging. Chronic rejection is mainly based on production of donor-specific antibodies that induce endothelial cell activation-a condition which phenotypically resembles chronic inflammation. Activated endothelial cells produce chemokines, and expression of adhesion molecules increases. Due to this pro-inflammatory microenvironment, leukocytes are recruited and transmigrate from the bloodstream across the endothelial monolayer into the vessel wall. This mononuclear infiltrate is a hallmark of transplant vasculopathy. Furthermore, expression profiles of different cytokines serve as clinical markers for the patient's outcome. Besides their effects on immune cells, activated endothelial cells support the migration and proliferation of vascular smooth muscle cells. In turn, muscle cell recruitment leads to neointima formation followed by reduction in organ perfusion and eventually results in tissue injury. Activation of endothelial cells involves antibody ligation to the surface of endothelial cells. Subsequently, intracellular signaling pathways are initiated. These signaling cascades may serve as targets to prevent or treat adverse effects in antibody-activated endothelial cells. Preventive or therapeutic strategies for chronic rejection can be investigated in sophisticated mouse models of transplant vasculopathy, mimicking interactions between immune cells and endothelium.
移植物排斥仍然是血管化实体器官移植后的主要障碍。内皮细胞构成移植移植物与宿主免疫系统之间的界面,是宿主免疫细胞的首要靶标。在急性细胞排斥反应期间,内皮细胞受到识别HLA I和II的自然杀伤细胞、巨噬细胞和T细胞的直接攻击,补体系统的激活导致内皮细胞溶解。既定的免疫抑制治疗形式提供了有效的治疗选择,但实体器官慢性排斥反应的治疗仍然具有挑战性。慢性排斥主要基于产生诱导内皮细胞活化的供体特异性抗体——这种情况在表型上类似于慢性炎症。活化的内皮细胞产生趋化因子,黏附分子的表达增加。由于这种促炎微环境,白细胞被募集并从血流中穿过内皮单层迁移到血管壁。这种单核浸润是移植血管病变的标志。此外,不同细胞因子的表达谱可作为患者预后的临床标志物。除了对免疫细胞的作用外,活化的内皮细胞还支持血管平滑肌细胞的迁移和增殖。反过来,肌肉细胞的募集导致新内膜形成,随后器官灌注减少,最终导致组织损伤。内皮细胞的活化涉及抗体与内皮细胞表面的结合。随后,细胞内信号通路被启动。这些信号级联反应可能成为预防或治疗抗体激活的内皮细胞不良反应的靶点。慢性排斥反应的预防或治疗策略可以在模拟免疫细胞与内皮细胞相互作用的复杂移植血管病变小鼠模型中进行研究。